| Jason G Bechard, MD | |
|
310 Sunnyview Ln, Kalispell, MT 59901-3129 | |
| (406) 751-5310 | |
| Not Available |
| Full Name | Jason G Bechard |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 29 Years |
| Location | 310 Sunnyview Ln, Kalispell, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285740845 | NPI | - | NPPES |
| 66980 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 8379 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wilcox Memorial Hospital | Lihue, HI | Hospital |
| Kauai Veterans Memorial Hospital | Waimea, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kauai Medical Clinic | 5092628479 | 115 |
| Kauai Veterans Memorial Hospital | 7911805114 | 16 |
News Archive
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
Valent BioSciences Corporation announced today it has filed worldwide patent applications claiming beneficial health effects of abscisic acid (S-ABA) in humans and animals. S-ABA is a naturally occurring substance found in all plants, including fruits and vegetables.
A laboratory blood test developed at Johns Hopkins for the diagnosis of a rare genetic red blood cell disorder also shows promise in identifying HELLP syndrome, a life-threatening high blood pressure condition affecting 1 percent of all pregnant women that causes hypertension along with end organ damage, researchers report in the May issue of the journal Experimental Hematology.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
Researchers from the Massachusetts Institute of Technology and Boston University have developed a system capable of quickly screening millions of yeast cells to measure protein aggregates.
› Verified 6 days ago
| Entity Name | Kauai Medical Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376596643 PECOS PAC ID: 5092628479 Enrollment ID: O20031111000540 |
News Archive
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
Valent BioSciences Corporation announced today it has filed worldwide patent applications claiming beneficial health effects of abscisic acid (S-ABA) in humans and animals. S-ABA is a naturally occurring substance found in all plants, including fruits and vegetables.
A laboratory blood test developed at Johns Hopkins for the diagnosis of a rare genetic red blood cell disorder also shows promise in identifying HELLP syndrome, a life-threatening high blood pressure condition affecting 1 percent of all pregnant women that causes hypertension along with end organ damage, researchers report in the May issue of the journal Experimental Hematology.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
Researchers from the Massachusetts Institute of Technology and Boston University have developed a system capable of quickly screening millions of yeast cells to measure protein aggregates.
› Verified 6 days ago
| Entity Name | Kauai Veterans Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467510743 PECOS PAC ID: 7911805114 Enrollment ID: O20040128000796 |
News Archive
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
Valent BioSciences Corporation announced today it has filed worldwide patent applications claiming beneficial health effects of abscisic acid (S-ABA) in humans and animals. S-ABA is a naturally occurring substance found in all plants, including fruits and vegetables.
A laboratory blood test developed at Johns Hopkins for the diagnosis of a rare genetic red blood cell disorder also shows promise in identifying HELLP syndrome, a life-threatening high blood pressure condition affecting 1 percent of all pregnant women that causes hypertension along with end organ damage, researchers report in the May issue of the journal Experimental Hematology.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
Researchers from the Massachusetts Institute of Technology and Boston University have developed a system capable of quickly screening millions of yeast cells to measure protein aggregates.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason G Bechard, MD 310 Sunnyview Ln, Kalispell, MT 59901-3129 Ph: (406) 751-5310 | Jason G Bechard, MD 310 Sunnyview Ln, Kalispell, MT 59901-3129 Ph: (406) 751-5310 |
News Archive
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
Valent BioSciences Corporation announced today it has filed worldwide patent applications claiming beneficial health effects of abscisic acid (S-ABA) in humans and animals. S-ABA is a naturally occurring substance found in all plants, including fruits and vegetables.
A laboratory blood test developed at Johns Hopkins for the diagnosis of a rare genetic red blood cell disorder also shows promise in identifying HELLP syndrome, a life-threatening high blood pressure condition affecting 1 percent of all pregnant women that causes hypertension along with end organ damage, researchers report in the May issue of the journal Experimental Hematology.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
Researchers from the Massachusetts Institute of Technology and Boston University have developed a system capable of quickly screening millions of yeast cells to measure protein aggregates.
› Verified 6 days ago
Charles S Charman, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 310 Sunnyview Lane, Kalispell, MT 59901 Phone: 406-752-5111 |